文献速递消化道肿瘤与早癌消化内镜

西方背景下胃十二指肠神经内分泌肿瘤内镜切除的结局:目标试验模拟

Outcomes of Gastroduodenal Neuroendocrine Tumors After Endoscopic Resection in the Western Setting - A Target Trial Emulation.
PubMed 文献 · Clin Gastroenterol Hepatol · 2026-09-29

这项多国回顾性研究纳入24中心10国的434例患者共444个胃十二指肠神经内分泌肿瘤,评估内镜切除的治愈性切除率、残留病率及复发。胃NET治愈性切除率51.6%、十二指肠NET 33.6%;残留病率分别为19.0%和10.8%,肿瘤相关死亡率0.2%。目标试验模拟显示ESD较C-EMR提高R0切除率(60.9% vs 45.6%)并降低局部复发。

要点

  • 胃十二指肠NET内镜切除治愈性切除率偏低,胃51.6%、十二指肠33.6%。
  • 残留病率胃19.0%、十二指肠10.8%,但肿瘤相关死亡率仅0.2%。
  • ESD较C-EMR提高R0切除率并降低4年和5年局部复发风险。

核心结论

  • 胃十二指肠NET内镜切除常为非治愈性切除,但复发率和肿瘤相关死亡率低。
  • ESD较C-EMR获得更高的校正R0切除率和更低的局部复发。

研究设计与样本

  • 多国回顾性研究,纳入24个中心、10个西方国家的连续接受内镜切除的胃十二指肠NET患者。
  • 共分析434例患者的444个肿瘤(胃304个、十二指肠140个),中位随访36个月。
  • 采用目标试验模拟比较ESD、C-EMR和改良EMR,并校正潜在混杂因素。

主要发现

  • 胃NET治愈性切除率为51.6%,十二指肠NET为33.6%。
  • 胃NET残留病率为19.0%,十二指肠NET为10.8%。
  • 胃十二指肠NET相关死亡率为0.2%。
  • ESD较C-EMR的R0切除率为60.9% vs 45.6%,风险差15.3个百分点。
  • ESD较C-EMR局部复发风险差4年为12.0个百分点、5年为14.3个百分点。

关键数值与推荐

  • 治愈性切除率:胃NET 51.6%,十二指肠NET 33.6%。
  • 残留病率:胃NET 19.0%,十二指肠NET 10.8%。
  • GD-NET相关死亡率0.2%。
  • ESD vs C-EMR的R0切除率60.9% vs 45.6%,风险差15.3个百分点。

临床怎么用

  • 内镜切除胃十二指肠NET后应关注非治愈性切除和残留病风险。
  • 在技术选择上,ESD可能较C-EMR提高R0切除并降低局部复发。
  • 需结合患者和切除技术选择,并完善治愈性切除标准。

局限性

  • 为回顾性研究,采用目标试验模拟而非随机对照设计。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Gastroduodenal neuroendocrine tumors (GD-NETs) are increasingly diagnosed. We aimed to: (1) evaluate the long-term outcomes following endoscopic resection (ER) of GD-NETs; and (2) compare the effectiveness of different ER techniques. METHODS: We conducted a multinational retrospective study (24 centers, 10 Western countries) of consecutive patients undergoing ER of GD-NETs. The main evaluated outcomes were the frequency of curative resection and residual disease. Additional evaluated outcomes included R0 resection rate and local recurrence. We performed a target trial emulation to compare endoscopic submucosal dissection (ESD), conventional endoscopic mucosal resection (C-EMR), and modified EMR for these outcomes, while adjusting for potential cofounders. RESULTS: We analyzed 444 GD-NETs (304 gastric, 140 duodenal) from 434 patients (median follow-up, 36 months). The curative resection rate was 51.6% for gastric neuroendocrine tumors (NETs) and 33.6% for duodenal NETs. The residual disease rate was 19.0% for gastric NETs and 10.8% for duodenal NETs. GD-NET-related mortality was 0.2%. Target trial emulation demonstrated that ESD, compared with C-EMR, achieved a significantly higher R0 resection (60.9% vs 45.6%; risk difference, 15.3 percent points [pp]) and lower risk of local recurrence at 4 (risk difference, 12.0 pp) and 5 years (risk difference, 14.3 pp). No significant differences were observed between the 3 ER approaches for other outcomes. CONCLUSIONS: GD-NETs were associated with frequent noncurative ER resections, but low recurrence and tumor-related mortality. ESD achieved a higher adjusted R0 resection rate and lower local recurrence compared with C-EMR. These results support the refinement of not only the curative resection criteria but also patient and ER technique selection.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Mendes F, Vieira RJ, Alípio M, et al. Outcomes of Gastroduodenal Neuroendocrine Tumors After Endoscopic Resection in the Western Setting - A Target Trial Emulation. Clin Gastroenterol Hepatol. 2026. PMID: 42805276. doi:10.1016/j.cgh.2026.09.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。